Tau and Amyloid- Conformational Change to  -Sheet Structures as Effectors in the Development of Alzheimer's Disease

QR Code

Tau and Amyloid- Conformational Change to  -Sheet Structures as Effectors in the Development of Alzheimer's Disease

None

Saved in:

Bibliographic Details
Main Authors:	Anda-Hernández, Martha A. De, León, Karla I. Lira-De, Mena, Raúl, Campos-Peña, Victoria, Meraz-Ríos, Marco A.
Format:	Electronic Book Chapter
Language:	English
Published:	IntechOpen 2012
Subjects:	Life Sciences
Online Access:	https://www.intechopen.com/chapters/32400
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Structural exposure of different microtubule binding domains determines the propagation and toxicity of pathogenic tau conformers in Alzheimer's disease.
by: Lenka Hromadkova, et al.
Published: (2025-06-01)

The Role and Pathogenesis of Tau Protein in Alzheimer’s Disease
by: Xiaoyue Hong, et al.
Published: (2025-06-01)

Pathological Stages of Abnormally Processed Tau Protein During Its Aggregation into Fibrillary Structures in Alzheimer’s Disease
by: García-Sierra, Francisco, et al.
Published: (2011)

A Pilot Study on Blood Concentration of β-Amyloid (40 and 42) and Phospho-Tau 181 in Horses
by: Valentina Gazzano, et al.
Published: (2025-06-01)

Tau Oligomers as Potential Drug Target for Alzheimer Disease (AD) Treatment
by: Kayed, Rakez
Published: (2011)

Cytoskeletal Proteins and Alzheimer’s Disease Pathogenesis: Focusing on the Interplay with Tau Pathology
by: Gege Jiang, et al.
Published: (2025-06-01)

Amyloid Imaging PET Ligands as Biomarkers for Alzheimer’s Disease, Preclinical Evaluation
by: Svedberg, Marie, et al.
Published: (2012)

Conformational Plasticity in Amyloid Assemblies: A Paradigm Shift from Structural Rigidity to Functional Adaptability
by: Alan H. Weible, et al.
Published: (2025-06-01)

Interplay Between Aging and Tau Pathology in Alzheimer’s Disease: Mechanisms and Translational Perspectives
by: Mohammed Alrouji, et al.
Published: (2025-06-01)

Relationship between tau-PET and quantitative susceptibility mapping in atypical Alzheimer’s disease
by: Neha Singh-Reilly, et al.
Published: (2025-07-01)

Brain‐derived tau to measure treatment effect in Alzheimer's disease and frontotemporal dementia
by: Cassandra Marotta, et al.
Published: (2025-04-01)

Anti-amyloid Monoclonal Antibodies for Alzheimer’s Disease: A New Hope? (Review)
by: I. A. Mazerkina
Published: (2025-04-01)

A novel view on Alzheimer’s disease pathogenesis: modern conceptof amyloid clearance
by: V. Yu. Lobzin, et al.
Published: (2018-11-01)

Exploring the association between mild behavioral impairment and plasma p‐tau217: Implications for early detection of Alzheimer's disease
by: Maryam Ghahremani, et al.
Published: (2025-04-01)

Diagnostic Challenge in Frontal Variant Alzheimer's Disease With Low Amyloid‐β PET Retention
by: Ryosuke Shimasaki, et al.
Published: (2025-07-01)

The Efficacy of Anti-amyloid Monoclonal Antibodies in Early Alzheimer’s Dementia: A Systematic Review
by: Alyaa Mostafa, et al.
Published: (2025-05-01)

Mannose Promotes β‐Amyloid Pathology by Regulating BACE1 Glycosylation in Alzheimer's Disease
by: Chensi Liang, et al.
Published: (2025-03-01)

Understanding the impact of amyloid beta targeted therapies on biomarkers and clinical endpoints in Alzheimer's disease
by: Ronald C. Petersen, et al.
Published: (2025-04-01)

High-intensity interval training reduces Tau and beta-amyloid accumulation by improving lactate-dependent mitophagy in rats with type 2 diabetes
by: Pouria Khosravi, et al.
Published: (2024-11-01)

Isoforms of Phosphorylated Tau as Potential Biomarkers for Alzheimer’s Disease: The Contribution of Mass Spectrometry-Based Proteomics
by: Marco Agostini, et al.
Published: (2025-06-01)

Use of Model‐Based Meta‐Analysis to Inform the Design of Early Clinical Trials of Anti‐Amyloid Beta Therapies in Alzheimer's Disease
by: Sagar S. Bachhav, et al.
Published: (2025-07-01)

Role of neuronal fabp in autophagy and amyloid-β pathology in a Drosophila model of Alzheimer disease
by: Byoungyun Choi, et al.
Published: (2025-12-01)

Neurotoxic amyloid β‐peptide and tau produce cytokine‐like effects on PMCA in glioblastoma cell lines, enhancing its activity and isoforms expression
by: María Berrocal, et al.
Published: (2025-08-01)

Mediating role of Interleukin-6 in the predictive association of diabetes with Hippocampus atrophy, Amyloid, Tau, and Neurofilament pathology at pre-clinical stages of diabetes-related cognitive impairment
by: Asma Hallab, et al.
Published: (2025-08-01)

Analytical and clinical validation of a high accuracy fully automated digital immunoassay for plasma phospho-Tau 217 for clinical use in detecting amyloid pathology
by: David Wilson, et al.
Published: (2025-07-01)

Solving the Amyloid Paradox: Unveiling the Complex Pathogenicity of Amyloid Fibrils
by: Maksim I. Sulatsky, et al.
Published: (2025-07-01)

Detection of hyperphosphorylated tau protein and &alpha;-synuclein in spinal cord of patients with Alzheimer&rsquo;s disease
by: Guo Y, et al.
Published: (2016-02-01)

Efficacy and safety of passive immunotherapies targeting amyloid beta in Alzheimer's disease: A systematic review and meta-analysis.
by: Reina Tonegawa-Kuji, et al.
Published: (2025-03-01)

Nose-to-brain delivery of targeted lipid nanoparticles as two-pronged β-amyloid nanoscavenger for Alzheimer's disease therapy
by: Yanyan Xu, et al.
Published: (2025-06-01)

Prevalence of cerebral amyloid angiopathy and its correlation with Alzheimer's disease and cognition in an autopsy‐confirmed cohort from China
by: Xiang‐Sha Yin, et al.
Published: (2025-04-01)

T-violating effect in $\nu_\tau (\bar{\nu}_\tau)-$nucleon quasielastic scattering
by: A. Fatima, M. Sajjad Athar and, S. K. Singh
Published: (2025-07-01)

Amyloid tumor of the breast
by: Makiko Mori, et al.
Published: (2019-02-01)

Cerebrospinal fluid β-amyloid1-42 levels in the differential diagnosis of Alzheimer's disease--systematic review and meta-analysis.
by: Jin-A Mo, et al.
Published: (2015-01-01)

Improved reconstruction of highly boosted $$\tau $$ τ -lepton pairs in the $$\tau \tau \rightarrow (\mu \nu _{\mu }\nu _{\tau })(\text {hadrons}+\nu _{\tau })$$ τ τ → ( μ ν μ ν τ ) ( hadrons + ν τ ) decay channels with the ATLAS detector
by: ATLAS Collaboration
Published: (2025-06-01)

Peripheral administration of blood from tau transgenic animals exacerbates brain tau-associated pathology.
by: Laura Vegas-Gomez, et al.
Published: (2025-01-01)

Peripheral administration of blood from tau transgenic animals exacerbates brain tau-associated pathology
by: Laura Vegas-Gomez, et al.
Published: (2025-01-01)

Hematopoietic Derived Fibrocytes: Emerging Effector Cells in Fibrotic Disorders
by: García-de-Alba, Carolina, et al.
Published: (2012)

Usos locativos de según y conforme
by: María Victoria Pavón Lucero, et al.
Published: (2017-12-01)

The two cut‐offs approach for plasma p‐tau217 in detecting Alzheimer's disease in subjective cognitive decline and mild cognitive impairment
by: Giulia Giacomucci, et al.
Published: (2025-04-01)

Mining Effector Proteins in Phytopathogenic Fungi
by: Cheng-yun, Li, et al.
Published: (2011)